BR112022023933A2 - Anticorpos direcionados a um complexo compreendendo hla-i não clássico e neoantígeno e seus métodos de uso - Google Patents
Anticorpos direcionados a um complexo compreendendo hla-i não clássico e neoantígeno e seus métodos de usoInfo
- Publication number
- BR112022023933A2 BR112022023933A2 BR112022023933A BR112022023933A BR112022023933A2 BR 112022023933 A2 BR112022023933 A2 BR 112022023933A2 BR 112022023933 A BR112022023933 A BR 112022023933A BR 112022023933 A BR112022023933 A BR 112022023933A BR 112022023933 A2 BR112022023933 A2 BR 112022023933A2
- Authority
- BR
- Brazil
- Prior art keywords
- hla
- neoantigen
- complex
- classical
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032886P | 2020-06-01 | 2020-06-01 | |
| US17/199,258 US11976120B2 (en) | 2020-06-01 | 2021-03-11 | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| PCT/US2021/035291 WO2021247608A1 (en) | 2020-06-01 | 2021-06-01 | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022023933A2 true BR112022023933A2 (pt) | 2023-04-11 |
Family
ID=78829884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022023933A BR112022023933A2 (pt) | 2020-06-01 | 2021-06-01 | Anticorpos direcionados a um complexo compreendendo hla-i não clássico e neoantígeno e seus métodos de uso |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11976120B2 (https=) |
| EP (1) | EP4157884A4 (https=) |
| JP (1) | JP7653513B2 (https=) |
| KR (1) | KR20230019469A (https=) |
| CN (1) | CN116157157A (https=) |
| AU (1) | AU2021283201A1 (https=) |
| BR (1) | BR112022023933A2 (https=) |
| CA (1) | CA3174102A1 (https=) |
| CL (1) | CL2022003299A1 (https=) |
| CO (1) | CO2022018430A2 (https=) |
| CR (1) | CR20220650A (https=) |
| DO (1) | DOP2022000265A (https=) |
| EC (1) | ECSP22097203A (https=) |
| IL (1) | IL298061A (https=) |
| JO (1) | JOP20220308A1 (https=) |
| MX (1) | MX2022015129A (https=) |
| PE (1) | PE20230374A1 (https=) |
| WO (1) | WO2021247608A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210253713A1 (en) * | 2018-07-23 | 2021-08-19 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use |
| US10981996B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US11976120B2 (en) | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US20240415884A1 (en) * | 2022-02-01 | 2024-12-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Molecules that bind to cd276 polypeptides |
| CN120077068A (zh) * | 2022-08-18 | 2025-05-30 | 英美偌科有限公司 | 多结构域结合分子 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8039218B2 (en) * | 2002-11-14 | 2011-10-18 | John Wayne Cancer Institute | Detection of cancer cells in body fluids |
| EP1872124A4 (en) * | 2005-04-19 | 2008-06-11 | Prediction Sciences Llc | DIAGNOSIS MARKET FOR BREAST CANCER TREATMENT AND PROGRESSION AND METHOD OF USE THEREOF |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| WO2010019921A2 (en) * | 2008-08-15 | 2010-02-18 | The Regents Of The University Of California | Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia |
| US20120178111A1 (en) * | 2009-09-23 | 2012-07-12 | Diamandis Eleftherios P | Methods and compositions for the detection of lung cancers |
| EP2699603B1 (en) | 2011-04-19 | 2016-03-02 | The United States of America As Represented by the Secretary Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| US10656156B2 (en) | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
| EP2961770A1 (en) | 2013-02-26 | 2016-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| IL263466B2 (en) | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| CN103773775B (zh) | 2014-01-26 | 2015-11-18 | 江苏省农业科学院 | 一种人源抗虫基因及其编码的抗Cry1B毒素独特型单链抗体与应用 |
| US9950077B2 (en) | 2014-06-20 | 2018-04-24 | Bioalliance C.V. | Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof |
| US10329348B2 (en) | 2014-10-23 | 2019-06-25 | Innate Pharma | Treatment of cancers using anti-NKG2A agents |
| US10544220B2 (en) | 2015-01-08 | 2020-01-28 | Genmab A/S | Bispecific antibodies against CD3 and CD20 |
| EP3475706B1 (en) | 2016-06-27 | 2021-08-11 | Juno Therapeutics, Inc. | Mhc-e restricted epitopes, binding molecules and related methods and uses |
| EP3573997A4 (en) | 2017-01-24 | 2020-12-09 | Abexxa Biologics, Inc. | METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER |
| CN112351795A (zh) | 2018-02-23 | 2021-02-09 | 安贝科思生物制剂公司 | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 |
| US20210253713A1 (en) | 2018-07-23 | 2021-08-19 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use |
| US20200291128A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| US10981997B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US10981996B1 (en) | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US11976120B2 (en) | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
-
2021
- 2021-03-11 US US17/199,258 patent/US11976120B2/en active Active
- 2021-06-01 KR KR1020227046390A patent/KR20230019469A/ko not_active Withdrawn
- 2021-06-01 AU AU2021283201A patent/AU2021283201A1/en not_active Abandoned
- 2021-06-01 US US18/000,493 patent/US20230303701A1/en active Pending
- 2021-06-01 CA CA3174102A patent/CA3174102A1/en active Pending
- 2021-06-01 BR BR112022023933A patent/BR112022023933A2/pt not_active Application Discontinuation
- 2021-06-01 IL IL298061A patent/IL298061A/en unknown
- 2021-06-01 PE PE2022002747A patent/PE20230374A1/es unknown
- 2021-06-01 CN CN202180057675.8A patent/CN116157157A/zh active Pending
- 2021-06-01 WO PCT/US2021/035291 patent/WO2021247608A1/en not_active Ceased
- 2021-06-01 JP JP2023517830A patent/JP7653513B2/ja active Active
- 2021-06-01 MX MX2022015129A patent/MX2022015129A/es unknown
- 2021-06-01 CR CR20220650A patent/CR20220650A/es unknown
- 2021-06-01 EP EP21818757.3A patent/EP4157884A4/en active Pending
-
2022
- 2022-11-15 JO JOJO/P/2022/0308A patent/JOP20220308A1/ar unknown
- 2022-11-24 DO DO2022000265A patent/DOP2022000265A/es unknown
- 2022-11-24 CL CL2022003299A patent/CL2022003299A1/es unknown
- 2022-12-19 CO CONC2022/0018430A patent/CO2022018430A2/es unknown
- 2022-12-23 EC ECSENADI202297203A patent/ECSP22097203A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2022000265A (es) | 2023-01-15 |
| CN116157157A (zh) | 2023-05-23 |
| AU2021283201A1 (en) | 2023-02-02 |
| KR20230019469A (ko) | 2023-02-08 |
| JP2023530037A (ja) | 2023-07-12 |
| CA3174102A1 (en) | 2021-12-09 |
| US20220033504A1 (en) | 2022-02-03 |
| PE20230374A1 (es) | 2023-03-06 |
| JP7653513B2 (ja) | 2025-03-28 |
| IL298061A (en) | 2023-01-01 |
| EP4157884A1 (en) | 2023-04-05 |
| ECSP22097203A (es) | 2023-02-28 |
| MX2022015129A (es) | 2023-03-24 |
| JOP20220308A1 (ar) | 2022-11-15 |
| CL2022003299A1 (es) | 2023-07-07 |
| CO2022018430A2 (es) | 2022-12-30 |
| EP4157884A4 (en) | 2024-06-19 |
| WO2021247608A1 (en) | 2021-12-09 |
| US20230303701A1 (en) | 2023-09-28 |
| CR20220650A (es) | 2023-05-25 |
| US11976120B2 (en) | 2024-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022023933A2 (pt) | Anticorpos direcionados a um complexo compreendendo hla-i não clássico e neoantígeno e seus métodos de uso | |
| BR112022024275A2 (pt) | Anticorpos que visam um complexo que compreende hla-i não clássico e neoantígeno e seus métodos de uso | |
| CL2020001333A1 (es) | Moléculas de unión b7-h3 novedosas, conjugados anticuerpo-fármaco de los mismos y métodos de uso de los mismos. (divisional solicitud 201802895) | |
| CO2020010277A2 (es) | Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl | |
| AR096895A2 (es) | Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) | |
| ECSP077978A (es) | Anticuerpos monoclonales anti-trkb y usos de los mismos | |
| GT200900271A (es) | Anticuerpos contra la il-25 | |
| PE20091520A1 (es) | Anticuerpos bivalentes biespecificos | |
| MX2013000366A (es) | Inmonoglubulinas de dominio variable doble y usos de las mismas. | |
| PA8626201A1 (es) | Conjugados de caliqueamicina | |
| NI200900022A (es) | Anticuerpo especifico de prlr y usos del mismo | |
| CL2012002329A1 (es) | Molecula de anticuerpo quimerico que se une a cd37 humano; molecula de adn que codifica la cadena pesada y la cadena liviana de las regiones variables del anticuerpo; vector de expresion y celula huesped que comprende dichos adn; composicion farmaceutica que comprende los anticuerpos; uso de la composicion en la supresion de celulas b (divi. sol. 2349-08) | |
| MX2022006893A (es) | Conjugado anticuerpo-farmaco anti-claudina y uso farmaceutico del mismo. | |
| CR11783A (es) | Molecula de union al antigeno capaz de unirse repetidamente a dos o mas moleculas de antigeno | |
| PE20211887A1 (es) | Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t | |
| CL2008003781A1 (es) | Anticuerpo bivalente biespecifico que comprende la cadena ligera y pesada de un anticuerpo que se une a un antigeno, y la cadena ligera y pesada de un anticuerpo que se une a un antigeno diferente, donde los dominios variables vl y vh estan cambiados el uno por el otro; metodo de preparacion; celula huesped; y composicion. | |
| AR083044A1 (es) | Anticuerpos anti-cd48 y usos de los mismos | |
| NI201300057A (es) | Mutantes fc de anticuerpos resistentes a proteasas activas | |
| BRPI0518209A (pt) | agentes de ligação especìficos à angiopoietina-2 | |
| CL2008002092A1 (es) | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. | |
| CR20180087A (es) | Inmunoconjugados de il22 | |
| AR122502A1 (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso | |
| AR085758A1 (es) | Antidotos anticoagulantes | |
| CO6361908A2 (es) | Composicion para dirigirse a las celulas dendriticas | |
| EA200701766A1 (ru) | Антитела против антигенов candida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |